Dapagliflozin

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including updates in mental health, cancer awareness and the vital importance of washing your hands. NEW YORK, Oct. 17, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Oct. 13-17, 2025. Hugel Inc. appoints Carrie Strom as Chief Executive Officer Carrie Strom is a 25-year pharmaceutical and aesthetics industry leader who previously served as Global President of Allergan Aesthetics. "My priority is to build on Hugel's leadership in South Korea and transform it into a global aesthetics powerhouse, raising the bar for how we serve customers and patients around the world," she said. Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint. Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics Waters Xevo CDMS delivers unmatched characterization for mega-mass biomolecules central to next-generation therapies. Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology Developed in collaboration with Eli Lilly and Company, this minimally invasive test provides clinicians with information that can help identify patients in early stages of cognitive decline who are unlikely to have Alzheimer's-related amyloid pathology. Global Handwashing Day 2025 Underscores the Power of Soap and Water to Save Lives Celebrated annually on October 15, this worldwide event reminds people that consistent hand hygiene is critical to preventing the spread of infectious diseases and protecting community health. Kohler Co. Launches Kohler Health, Ushering in a New Era of Health and Wellness in the Home As health and wellness continue to expand to the home setting, the bathroom stands as an untapped hub of vital health data and information. Every day, we flush away insights that could help us better understand our bodies and our health. Kohler Health is challenging people to re-imagine how they think about the bathroom. Friendship is Fitness: New Research From Peerspace Shows Social Connection as Key to Health Healthy social connection depends on getting the right mix of interactions that meet our individual social needs. Peerspace's new quiz introduces eight distinct social connection personality types – from The Deep Diver to The Silly Goose – each reflecting a unique way people experience and seek out connection. Clear Channel Outdoor and Blood Cancer United Team Up on Billboard Campaign to Reach More People Affected by Blood Cancer The out-of-home campaign introduces The Leukemia & Lymphoma Society's new name, Blood Cancer United, to engage more communities and increase awareness of blood cancer. Pink Aid Celebrates 15 Years of Compassion and Support for Breast Cancer Patients Facing Financial Crisis Created in 2011 by Amy Katz, Andrew Mitchell-Namdar, Renee Mandis, and Amy Gross, Pink Aid was born from a critical need: while treatments for breast cancer have advanced, one in three patients still faces financial collapse. Many lose their jobs, delay care, or risk eviction while battling for their lives. The founders envisioned a community of care to ensure patients never have to choose between treatment and basic necessities like food and shelter. 81% of Americans Say Mental Health Support Can't Wait - They Expect It Within Hours, New CallTrackingMetrics Report Finds The report paints a picture of a growing dilemma in access to behavioral health care: timeliness. When care is delayed, it's denied. One in five Americans said they reached out to mental health or addiction treatment providers for help, but never heard back. Twin Health and Peloton Partner to Transform Metabolic Health The unique partnership will bring Peloton's world-class fitness and wellness content to Twin's AI digital twin program, proven to treat diabetes, prediabetes and obesity while reducing reliance on medications. On World Mental Health Day, NAMI Announces New Scientific Advisory Council to Advance Hope Through Research The council unites leading scientists, clinicians, and advocates to ensure that cutting-edge research and lived experience together shape the future of mental health care. Trust and Transparency Rule: How Scientists Choose Antibodies in 2025 Drawing on feedback from hundreds of scientists, the 2025 report highlights evolving trends in antibody selection, purchasing behavior, and usage. Karmanos Shines a Green Light on Liver Cancer in October: Know the Risks, Know the Signs According to the American Cancer Society, more than 800,000 people are diagnosed with liver cancer around the world each year. Here in the U.S., over 42,200 new cases of liver cancer are estimated to occur in 2025. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Bengaluru: Eli Lilly's experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials , the company said on Wednesday, as it seeks to widen its lead in the rapidly growing market for GLP-1 drugs . The oral drug, orforglipron, is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatide, sold under the brand names Mounjaro and Zepbound. Lilly and its Danish rival Novo Nordisk, market leaders with their injectable drugs, are racing to launch oral weight-loss treatments, which still require approval by the U.S. Food and Drug Administration. In one of the studies, Lilly's pill helped lower A1C, a measure of blood sugar over time, by up to 1.7% compared to 0.8% with 10 mg dose of AstraZeneca's drug dapagliflozin, sold under the brand name Farxiga. The head-to-head trial was conducted in adults with type 2 diabetes inadequately controlled on metformin, a widely used drug to treat high blood sugar levels. In the other trial, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine. In both trials, orforglipron showed weight loss and improvements in multiple cardiovascular risk factors, the company said. Patients received either a 3 mg, 12 mg or 36 mg dose of orforglipron over 40 weeks across the studies. In a previous head-to-head trial in adults with type 2 diabetes, orforglipron lowered average blood sugar and weight more effectively than Novo's older GLP-1 pill Rybelsus. "Together, these results reinforce orforglipron's potential to become a new standard of care for people living with type 2 diabetes," said Jeff Emmick, senior vice president of product development, Lilly Cardiometabolic Health. Results from another trial is expected in the first quarter of 2026. Lilly plans to submit orforglipron for the treatment of type 2 diabetes to global regulatory agencies in 2026, while submission for the obesity treatment is set to occur by this year end. (Reporting by Sriparna Roy and Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)